Offers customers a 12-week clinical trial programme that delivers maximum speed, but does not compromise quality
Pharmaceutical services business Patheon has launched its updated programme Quick to Clinic, making it the only CDMO to offer customers an accelerated 12-week clinical trial material programme with stability data with a variety of flexible dosage forms.
The Quick to Clinic offering includes a month of clinical trial stability studies, provides customers access to six flexible dosage forms and decreases the wait time from receipt of API for clinical trial materials for First in Human trials by one month. Patheon customers can now receive high-quality Phase I clinical trial materials in as few as 12 weeks and with stability data, delivering maximum speed without compromising quality.
The six Quick to Clinic dosage forms offered by Patheon include blend in capsule, API in capsule, blend in bottle, API in bottle, oral liquid and softgel.
With expansive resources and expertise, Quick to Clinic offers customers the ability to meet their unique scientific requirements with capabilities spanning from formulation development and manufacturing to clinical packaging and distribution. First launched in 2009, Patheon has refreshed the Quick to Clinic programme and expanded it to include its sites in Cincinnati, Ohio; Milton Park, UK; Tilburg, the Netherlands; and Toronto, Canada.
'We are excited about the enhanced Quick to Clinic programme and the benefit that it will provide to our customers,' said Mike Lehmann, President, PDS and Executive Vice President, Global Sales and Marketing, Patheon. 'We are now the only CDMO that can offer customers a 12-week clinical trial programme that delivers maximum speed, but does not compromise quality.'